A phase II Study of OSI-774 in unresectable hepatocellular carcinoma.

被引：0
|
作者：
Thomas, MB
Faria, S
Tamm, E
Rashid, A
Charnsangavej, C
Dancey, J
Abbruzzese, J
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] NCI, Bethesda, MD 20892 USA
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6092S / 6092S
页数：1
相关论文
共 50 条
  • [41] Outcomes of stereotactic body radiotherapy for unresectable hepatocellular carcinoma.
    Zhao, Yizhou
    Dunne, Emma
    Ma, Roy
    Liu, Mitchell
    Beaton, Laura
    Yeung, Rosanna
    Lund, Chad R.
    Schellenberg, Devin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [42] Phase H study of imatinib in unresectable hepatocellular carcinoma
    Lin, Albert Y.
    Fisher, George A.
    So, Samuel
    Tang, Christopher
    Levitt, Lee
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 84 - 88
  • [43] Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma
    Park, Joong-Won
    Koh, Young Hwan
    Kim, Hyun Beom
    Kim, Hwi Young
    An, Sangbu
    Choi, Joon-Il
    Woo, Sang Myung
    Nam, Byung-Ho
    JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1336 - 1342
  • [44] A phase II study of the combination of bevacizumab and eirlotinilb in patients with patients with unresectable hepatocellular carcinoma
    Thomas, M.
    Iwasaki, M.
    Higginbotham, K.
    Lozano, R.
    Glover, K.
    Abbruzzese, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 14 - 15
  • [45] Efficacy and safety of a phase II study of sorafenib plus gemcitabine in advanced hepatocellular carcinoma.
    Srimuninnimit, V.
    Sriuranpong, V.
    Suwanvecho, S.
    Soparattanapaisarn, N.
    Ithimakin, S.
    Akewanlop, C.
    Tanasanvimon, S.
    Parinyanitikul, N.
    Kiatikajornthada, N.
    Suwanrusme, H.
    Chaiyarat, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
    Gruenwald, V.
    Wilkens, L.
    Gebel, M.
    Greten, T. F.
    Kubicka, S.
    Ganser, A.
    Manns, M. P.
    Malek, N. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] A phase II study of imatinib mesylate (IM) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Lin, AY
    Fisher, G
    So, S
    Tang, C
    Levitt, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 363S - 363S
  • [48] Real-world study of anlotinib monotherapy and combination therapy for unresectable hepatocellular carcinoma.
    Lei, Yi
    He, Jingchang
    Kang, Shuai
    Liu, Dingli
    Yu, Wenxuan
    Wang, Kunyuan
    Chen, Huaiyu
    Cheng, Yang
    Zhu, Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
    Thomas, Melanie B.
    Chadha, Romil
    Glover, Katrina
    Wang, Xuemei
    Morris, Jeffrey
    Brown, Thomas
    Rashid, Asif
    Dancey, Janet
    Abbruzzese, James L.
    CANCER, 2007, 110 (05) : 1059 - 1067
  • [50] Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
    Sangro, Bruno
    Galle, Peter R.
    Kelley, Robin Kate
    Charoentum, Chaiyut
    De Toni, Enrico N.
    Ostapenko, Yuriy
    Heo, Jeong
    Cheng, Ann-Lii
    Vogel, Arndt
    Marcovitz, Michelle
    Abraham, Jayne
    Patel, Nikunj
    Negro, Alejandra
    Abou-Alfa, Ghassan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345